-
Mashup Score: 0Enfortumab Vedotin Plus Pembrolizumab Shows Survival Advantage in Advanced Urothelial Carcinoma - 5 month(s) ago
Read the full article here
Source: cancernursingtoday.comCategories: Expert PicksTweet
-
Mashup Score: 3
Read the full article here
Source: www.docwirenews.comCategories: Expert PicksTweet-
🆕@DAMMGoodSleep details how having #sleepdisorders can impact a person’s love life and even sexual performance. Dr. Morse also discusses the negative impact that lack of sleep can have on physicians. #sleephealth #sexhealth #relationshipadvice https://t.co/rYYEQO9Oti https://t.co/WdDoVzvhtk
-
-
Mashup Score: 0Guillermo Garcia-Manero, MD, Looks Ahead to SOHO 2024 - 6 month(s) ago
Read the full article here
Source: bloodcancerstoday.comCategories: Expert PicksTweet-
Thoughts
-
-
Mashup Score: 3ESAs Before Transfusions Improve Outcomes Versus After Transfusions in MDS | Blood Cancers Today - 6 month(s) ago
Read the full article here
Source: bloodcancerstoday.comCategories: Expert PicksTweet-
Among patients with anemia related to lower-risk #MDS, receiving ESAs before transfusions improved outcomes versus after transfusions. Read more about the study presented at #EHA2024 by Abdessamia Gandoul, MD, of @CHU_Grenoble. 📰 https://t.co/BT68oQqym4 https://t.co/acBhrj5Ni7
-
-
Mashup Score: 4
Read the full article here
Source: www.docwirenews.comCategories: Expert PicksTweet-
🚨 A late-breaking abstract presented at #ASCO24 has emphasized the potential role of ctDNA-based minimal residual disease in tailoring treatment strategies for patients with locally advanced #rectalcancer. ❇️ Read more about the phase 3 UNION trial: https://t.co/NINcBBmk2R
-
-
Mashup Score: 4
Read the full article here
Source: www.docwirenews.comCategories: Expert PicksTweet-
🚨 A late-breaking abstract presented at #ASCO24 has emphasized the potential role of ctDNA-based minimal residual disease in tailoring treatment strategies for patients with locally advanced #rectalcancer. ❇️ Read more about the phase 3 UNION trial: https://t.co/NINcBBmk2R
-
-
Mashup Score: 4
Read the full article here
Source: www.docwirenews.comCategories: Expert PicksTweet-
🚨 A late-breaking abstract presented at #ASCO24 has emphasized the potential role of ctDNA-based minimal residual disease in tailoring treatment strategies for patients with locally advanced #rectalcancer. ❇️ Read more about the phase 3 UNION trial: https://t.co/NINcBBmk2R
-
-
Mashup Score: 5Daniel Coyne on Twitter - 9 month(s) ago
Read the full article here
Source: endpts.comCategories: Expert PicksTweet-
Daprodustat (Jesduvroq) GSK pulls plans to market anemia drug in EU and other markets, citing 'reduced opportunity' - https://t.co/XSRLX6w4wF https://t.co/hWpfLZ1kLm
-
-
Mashup Score: 2CheckMate 8HW: Nivolumab Plus Ipilimumab Offers Better PFS for mCRC Over Chemotherapy Alone | Docwire News - 11 month(s) ago
At ASCO GI 2024, Dr. Thierry Andre presented the first results of the CheckMate 8HW study on the use of nivolumab plus ipilimumab versus chemotherapy and nivolumab monotherapy.
Source: www.docwirenews.comCategories: Expert PicksTweet-
Earlier today at @ASCO #GI24, Dr. Thierry Andre presented results of the CheckMate 8HW study that demonstrated the benefits of nivolumab plus ipilimumab over chemotherapy alone for #ColorectalCancer. Learn More: https://t.co/P7LPt8t3Ll
-
-
Mashup Score: 2
Dr. Christopher Lieu gives an overview of some of the top presentations and data to look out for at ASCO GI 2024, and discusses the importance of the event.
Source: www.docwirenews.comCategories: Expert PicksTweet-
We spoke with Dr. Christopher Lieu from @CUCancerCenter on the upcoming @ASCO #GI24 conference, including presentations to keep an eye on and the importance of the event for researchers and physicians. Watch now: https://t.co/DgXZEDrOst https://t.co/oExmTNmIOb
-
Thoughts